EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Parthanatos drives cognitive decline in repeated brain trauma: MSC-derived exosomes as a novel therapeutic strategy

Heba Mohammed Refat M Selim, Amira A El-Gazar, Dalaal M Abdallah, Hagar B Abo-Zalam, Ghada M Ragab, Ahmed N Abdallah, Rabab A El-Gazar, Sultan Alshehri, Einas M Yousef, Rayan Ballal, Sahar N Aljarallah, Asmaa Saleh und 4 weitere

Frontiers in Pharmacology · 02.09.2025 · 16

DOI: 10.3389/fphar.2025.1622018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.09.2025. Verfasst von Heba Mohammed Refat M Selim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AlMaarefa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Repetitive traumatic brain injury (RTBI) represents a cumulative neurological insult associated with progressive neurodegeneration and limited therapeutic options. In this study, we uniquely evaluate the neuroprotective potential of mesenchymal stem cell (MSC)-derived exosomes in a rat model of RTBI, an area scarcely explored.

Methods

RTBI was induced via a controlled mechanical impact to the skull once every day for 5 days. MSC-derived exosomes were administered 24 h after the final insult in two paradigms: a single dose (MSC-Ex1) with 2 weeks of follow-up, and a dual dose (MSC-Ex2) given 1 week apart, with sacrifice 1 week later. Rats were assigned to four groups: control, RTBI, RTBI + MSC-Ex1, and RTBI + MSC-Ex2.

Results

MSC-derived exosome regimens comparably restored cognitive performance in the Novel Object Recognition and Y-maze tests. While both treatment paradigms preserved cortical histoarchitecture, the double-dose regimen led to a more pronounced restoration compared to the moderate tissue recovery observed in the single-dose group. Crucially, this work identifies parthanatos inhibition as a novel mechanistic axis for MSC-derived exosomes-mediated neuroprotection. MSC-derived exosomes attenuated excitotoxicity and oxidative stress, quelling the parthanatos cascade by suppressing PARP1, PAR polymers, nuclear AIF and MIF, as well as calpain, key executors of this caspase-independent cell death pathway. Additionally, MSC-derived exosomes normalized cyclophilin B and Hsp70 levels, suggesting their compensatory role in modulating the endogenous stress response.

Conclusion

Overall, these findings demonstrate that MSC-derived exosomes counteract RTBI-induced neurodegeneration through multifaceted mechanisms, with parthanatos suppression at the core. Importantly, the dual-dosing regimen conferred no significant benefit over the single dose, highlighting the therapeutic promise of early intervention. This study positions MSC-derived exosomes as a novel, cell-free therapy capable of intercepting RTBI-induced neuropathology by targeting an under recognized form of programmed cell death.

Schlagwörter

Stichwörter der Autor:innen

NAD +PARP1calpaincyclophilin Bexosomesoxidative stressparthanatos

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, October 6 University, Giza, Egypt.
  • Department of Pharmacology & Toxicology, Cairo University, Cairo, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Misr University for Science and Technology, Giza, Egypt.
  • Hormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
  • Department of Clinical Pharmacy, October 6 University, Giza, Egypt.

Förderung

  • AlMaarefa University

Zitieren

APA

Refat M Selim, H. M., El-Gazar, A. A., Abdallah, D. M., Abo-Zalam, H. B., Ragab, G. M., Abdallah, A. N., El-Gazar, R. A., Alshehri, S., Yousef, E. M., Ballal, R., Aljarallah, S. N., Saleh, A., Abou Chahin, N. F., Alsammak, N. S., Mandil, R. A., & El-Abhar, H. S. (2025). Parthanatos drives cognitive decline in repeated brain trauma: MSC-derived exosomes as a novel therapeutic strategy. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1622018

Vancouver

Refat M Selim HM, El-Gazar AA, Abdallah DM, Abo-Zalam HB, Ragab GM, Abdallah AN, et al. Parthanatos drives cognitive decline in repeated brain trauma: MSC-derived exosomes as a novel therapeutic strategy. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1622018

BibTeX
@article{RefatMSelim2025,
  author = {Refat M Selim, Heba Mohammed and El-Gazar, Amira A and Abdallah, Dalaal M and Abo-Zalam, Hagar B and Ragab, Ghada M and Abdallah, Ahmed N and El-Gazar, Rabab A and Alshehri, Sultan and Yousef, Einas M and Ballal, Rayan and Aljarallah, Sahar N and Saleh, Asmaa and Abou Chahin, Nada F and Alsammak, Naheda S and Mandil, Rasha A and El-Abhar, Hanan S},
  title = {Parthanatos drives cognitive decline in repeated brain trauma: MSC-derived exosomes as a novel therapeutic strategy},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1622018}
}
Kostenlos starten →